Chapel Hill, NC, United States of America

Daniel W Copeland

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Daniel W. Copeland

Introduction

Daniel W. Copeland is an accomplished inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of chronic inflammatory lung diseases. With a total of 2 patents, his work has the potential to impact many patients suffering from these conditions.

Latest Patents

One of his latest patents is an aqueous solution comprising a glutathione salt. This disclosure provides pharmaceutical preparations, products, and methods relating to ARINA-1 for use in treating patients with chronic inflammatory lung diseases, such as lung transplant, cystic fibrosis (CF), non-CF bronchiectasis, chronic obstructive pulmonary disease (COPD), and other inflammatory lung diseases. This innovative approach aims to improve the quality of life for individuals affected by these serious health issues.

Career Highlights

Daniel W. Copeland is currently associated with Renovion, Inc., where he continues to develop groundbreaking solutions in the pharmaceutical industry. His expertise and dedication to innovation have positioned him as a key figure in his field.

Collaborations

Throughout his career, Daniel has collaborated with notable professionals, including Edward J. Delaney and Carolyn Durham. These partnerships have fostered a collaborative environment that enhances the development of new ideas and solutions.

Conclusion

Daniel W. Copeland's contributions to the field of pharmaceuticals, particularly through his patents, demonstrate his commitment to improving healthcare outcomes. His work continues to inspire innovation in the treatment of chronic inflammatory lung diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…